cohort one year, 72% of the patients had partial and 13% had complete response, with worse response for patients with severe AA and a longer interval between diagnosis and IST (more than 6 months). Severe adverse events were mainly linked to infections (24%), hemorrhages (6%), and elevated liver function tests (5%). Overall at 12 months, 9.7% of patients required second line IST and 15.6% received transplantation. Fifty-five patients died during the study mainly because of infections (53%). Factors predicting independently worse survival were age over 40 years, neutrophils less than 0.5 3 10 9 /L, male gender and longer delay between diagnosis and hATG (>6 months period). This study does illustrate the results of ATGAM with CSA in a true-life perspective and confirms ATGAM as standard of care IST to treat patients with AA not eligible for HSCT. 
| I N TR ODU C TI ON
Acquired aplastic anemia (AA), a rare disease (2 per million in Europe) associated with marrow failure, can be treated either by immunosuppressive therapy (IST) or by allogeneic hematopoietic stem cell transplantation (HSCT). While HSCT is the preferred treatment in younger patients (<40 years) with available HLA-identical sibling donor HSCT, IST is the gold standard approach for the others. [1] [2] [3] Since the seminal German randomized trial, the reference IST includes a combination of antithymocyte globulin (ATG) with cyclosporine (CSA). 4, 5 For patients with nonsevere AA (NSAA) who are transfusion dependent, the combination of ATG and CSA is superior to CSA alone, with a higher response rate, higher blood counts, and improved disease-free survival. 6 For severe AA (SAA), the combination of ATG and CSA results in a response rate of roughly 60% to 70% of patients, as first line therapy. 1, 3, [7] [8] [9] Historically, horse ATG (hATG) has been used as first line IST for AA, while rabbit ATG (rATG) tended to be used for relapsed AA, at least in Europe. 1, 3 Lymphoglobuline (horse ATG, Genzyme) was withdrawn from most by NIH published in 2011 demonstrated that the response rates and survival with hATG (ATGAM) was significantly better than rabbit ATG. 10 Rabbit ATG (thymoglobulin, Genzyme) in combination with CSA, as firstline IST, was evaluated prospectively in a multicenter, European, phase 2 pilot study, in 35 patients with aplastic anemia and compared with historical controls who received hATG. This later study also showed lower response and overall survival using rabbit ATG. 8 Other retrospective studies also indicate a significantly worse response rate and survival for AA patients treated with rATG in Europe and United States. 9, [11] [12] [13] [14] [15] [16] [17] [18] In light of this evidence, European hematologists petitioned with their country health authorities to develop a procedure to make ATGAM available to certain patients. This resulted in the establishment of a program referred to as the patient-named authorization for temporary use (ATU) program that allows certain patients to be treated with ATGAM 
| Cases identification
For the purpose of the study, a questionnaire was designed on behalf of the French reference center for aplastic anemia (national rare disease network) to collect informations from treating centers on patient-, and disease characteristics, and on outcomes. We identify 635 patients who prospec- 
| Procedures
Minimal diagnostic panel of aplastic anemia required to enter the study were a complete blood count, a bone marrow biopsy, and a bone marrow karyotype analysis. The ATU program is associated with a protocol for therapeutic use. ATGAM was homogeneously administered in hospitalized patients at a dose of 40 mg/kg/day for 4 days. CSA was administered with the dose adjusted to maintain trough blood levels of 200 to 400 ng per milliliter for one year and then decrease to stop before end of year 2. Antimicrobial prophylaxis was heterogeneous among the different centers according to local policy. Blood products transfusions were provided according to national guidelines.
| Definitions
Patients were classified before ATGAM treatment as having verysevere, severe or nonsevere disease according to usual criteria. 15, 19 Paroxysmal nocturnal hemoglobinuria clone were considered positive in flow cytometry if more than 0.1% of neutrophils were deficient of glycosylphosphatidylinositol-anchored proteins on the cell surface.
Criteria for response to treatment follow the British Committee for in relapse if they failed to respond to previous treatment with either horse or rabbit ATG more than one year before current treatment with ATGAM (regardless of the severity of the AA) 33/465 (7.1%).
We did not have enough data for some of the patients to allow classification 27/465 (5.8%).
| Statistical analysis
Descriptive statistics were reported as mean, standard deviation, median, and range for continuous variables and frequencies and proportions for categorical variables.
The Kaplan-Meier method was used to estimate overall survival rates, and a 2-sided log-rank test was used to test the equality of survival functions in different subgroups. Survival data were censored as of the date of last contact.
Probabilities of response and of new therapies were calculated by using the cumulative incidence estimator to accommodate competing risks. For response death, new IST treatment, or HSCT were competing risks. Comparisons between cumulative incidence curves were performed using the Gray test.
Multivariate analyses were performed to assess independent predictors of response at 12 months. Backward stepwise logistic regression methods included variables that demonstrated significant associations (P < .10) in the univariate models. Similarly, Cox proportional hazards regression model was used to assess predictors of the overall survival. Two-sided P < .05 was considered statistically significant. Statistical analyses were performed with the SAS 9.4 (SAS Institute, Cary, North Carolina).
| RE S U L TS

| Patient and disease characteristics
From September 2011 to March 2017, 465 patients received ATGAM as first line treatment (n 5 379; 81.5%), or for refractory (n 5 26) or relapsed disease (n 5 33) and were included in this survey. Median age was 39.4 years and 235 (53.8%) patients were male. The median follow-up was 13.5 months with 60% of the patients being followed for a minimum of one year. Most patients were adult but 25.9% were children (less than 18 years). Baseline patient, disease-and treatment-characteristics of the 438 patients who have enough data to be classified are summarized in Table 1 . Table S1 ). When we restricted this analysis to the patients who were treated in first line (relapse and refractory patients were excluded), the only factor 
| Second line treatment after hATG
We also estimated the CumI of second line treatment with the association hATG plus CSA (i.e., first treatment failure), which was 9.7% at 12 
| Overall survival
Overall survival (OS) and survival by treatment group were also estimated ( Figure 1A ,B, respectively). The 12-and 24-months Kaplan- Figure 1C . Overall survival is significantly better for patients younger than 15 years when compared with patients aged older than 40. Worst overall survival was observed for patients older than 40. Moreover, in the group of 379 patients who received ATGAM plus CSA as first line treatment, OS was impacted by the severity of the disease (significant worst outcome for patients with very severe disease, Figure 1D ). When we analyzed factors predicting overall survival, age over 40 years, neutrophils less than 0.5 3 10 9 /L, male gender and longer delay between diagnosis and treatment predicted independently for worse outcome (Supporting Information Table S2 ). In the group of patients who were treated first line (moderate, severe, and very severe aplastic anemia), factors associ- Table 3 .
| D I SCUSSION
IST using the combination of ATG plus CSA is associated with response rates between 60% and 80% with current 5-year survival rates of around 75-85%. 1, 15, 21, 22 With possibly the exception of Eltrombopag, 23 any attempt to add or substitute any other IST agent (like mycophenolate or sirolimus) to this gold standard drug combination has been a failure in phase II/III during the past 15 years. 3 While horse ATG (ATGAM) has been demonstrated to be significantly better to rabbit ATG in the setting of a randomized clinical trial 24 with similar results seen in a prospective case-control European study (historical controls patients treated with hATG), 8 this finding were subject to controversies. 9, [11] [12] [13] [14] [15] [16] [17] [18] In a recent meta-analysis, Hayakawa et al. 10 searched online databases for studies that compared the two ATGs brand for AA, including both randomized and nonrandomized con- Although expected from previous studies, 1, 3, 7, 15, 21, 22, 28 low neutrophil counts were also associated with bad prognosis. We also found a detrimental effect of the delay between diagnosis and IST, best results being obtained for patients treated in the first 6 months after diagnosis. Male gender was also associated with overall survival in our study, which is difficult to explain. The Basel group did find in the early 1990s that female gender was associated with worse response to ATG alone 29 but no with overall survival.
Androgens were the first drug associated with response in idiopathic ClinicalTrials.gov number, NCT02099747) in Europe.
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